These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 15276986)

  • 1. Characterization of four very virulent Argentinian strains of Marek's disease virus and the influence of one of those isolates on synergism between Marek's disease vaccine viruses.
    Buscaglia C; Nervi P; Risso M
    Avian Pathol; 2004 Apr; 33(2):190-5. PubMed ID: 15276986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host genetic resistance to Marek's disease sustains protective efficacy of herpesvirus of turkey in both experimental and commercial lines of chickens.
    Chang S; Xie Q; Dunn JR; Ernst CW; Song J; Zhang H
    Vaccine; 2014 Apr; 32(16):1820-7. PubMed ID: 24530405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative evaluation of the protective efficacy of rMd5deltaMeq and CVI988/ Rispens against a vv+ strain of Marek's disease virus infection in a series of recombinant congenic strains of White Leghorn chickens.
    Chang S; Ding Z; Dunn JR; Lee LF; Heidari M; Song J; Ernst CW; Zhang H
    Avian Dis; 2011 Sep; 55(3):384-90. PubMed ID: 22017035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of cell associated vaccines against Marek's disease virus grown in a continuous cell line from chickens.
    Geerligs H; Quanz S; Suurland B; Spijkers IE; Rodenberg J; Davelaar FG; Jongsma B; Kumar M
    Vaccine; 2008 Oct; 26(44):5595-600. PubMed ID: 18706949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection provided by Rispens CVI988 vaccine against Marek's disease virus isolates of different pathotypes and early prediction of vaccine take and MD outcome.
    Ralapanawe S; Walkden-Brown SW; Renz KG; Islam AF
    Avian Pathol; 2016; 45(1):26-37. PubMed ID: 26503904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens.
    Lee LF; Kreager KS; Arango J; Paraguassu A; Beckman B; Zhang H; Fadly A; Lupiani B; Reddy SM
    Vaccine; 2010 Feb; 28(5):1294-9. PubMed ID: 19941987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains.
    de Boer GF; Groenendal JE; Boerrigter HM; Kok GL; Pol JM
    Avian Dis; 1986; 30(2):276-83. PubMed ID: 3015113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Marek's disease field isolates by the "best fit" pathotyping assay.
    Dudnikova E; Norkina S; Vlasov A; Slobodchuk A; Lee LF; Witter RL
    Avian Pathol; 2007 Apr; 36(2):135-43. PubMed ID: 17479374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination-challenge interval markedly influences protection provided by Rispens CVI988 vaccine against very virulent Marek's disease virus challenge.
    Islam T; Walkden Brown SW; Renz KG; Fakhrul Islam AF; Ralapanawe S
    Avian Pathol; 2013 Dec; 42(6):516-26. PubMed ID: 24098951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection.
    Baigent SJ; Smith LP; Nair VK; Currie RJ
    Vet Immunol Immunopathol; 2006 Jul; 112(1-2):78-86. PubMed ID: 16682084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A deletion in the glycoprotein L (gL) gene of U.S. Marek's disease virus (MDV) field strains is insufficient to confer increased pathogenicity to the bacterial artificial chromosome (BAC)-based strain, RB-1B.
    Shaikh SA; Katneni UK; Dong H; Gaddamanugu S; Tavlarides-Hontz P; Jarosinski KW; Osterrieder N; Parcells MS
    Avian Dis; 2013 Jun; 57(2 Suppl):509-18. PubMed ID: 23901769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of Marek's disease virus (MDV) glycoprotein-, lytic antigen pp38- and transformation antigen Meq-encoding genes: association of meq mutations with MDVs of high virulence.
    Shamblin CE; Greene N; Arumugaswami V; Dienglewicz RL; Parcells MS
    Vet Microbiol; 2004 Sep; 102(3-4):147-67. PubMed ID: 15327791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease.
    Witter RL; Kreager KS
    Avian Dis; 2004 Dec; 48(4):768-82. PubMed ID: 15666858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus.
    Karpathy RC; Firth GA; Tannock GA
    Aust Vet J; 2002; 80(1-2):61-6. PubMed ID: 12180882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biocharacteristics shared by highly protective vaccines against Marek's disease.
    Gimeno IM; Witter RL; Hunt HD; Reddy SM; Reed WM
    Avian Pathol; 2004 Feb; 33(1):59-68. PubMed ID: 14681069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Marek's disease herpesvirus vaccine virus genome load in feather tips with protection, using an experimental challenge model.
    Baigent SJ; Smith LP; Currie RJ; Nair VK
    Avian Pathol; 2007 Dec; 36(6):467-74. PubMed ID: 17994325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective efficacy of a recombinant bacterial artificial chromosome clone of a very virulent Marek's disease virus containing a reticuloendotheliosis virus long terminal repeat.
    Mays JK; Black-Pyrkosz A; Spatz S; Fadly AM; Dunn JR
    Avian Pathol; 2016 Dec; 45(6):657-666. PubMed ID: 27258614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek's disease virus.
    Nazerian K; Witter RL; Lee LF; Yanagida N
    Avian Dis; 1996; 40(2):368-76. PubMed ID: 8790888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-γ influences immunity elicited by vaccines against very virulent Marek's disease virus.
    Haq K; Elawadli I; Parvizi P; Mallick AI; Behboudi S; Sharif S
    Antiviral Res; 2011 Jun; 90(3):218-26. PubMed ID: 21501630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating hypervirulent Marek's disease viruses in vaccinated chicken flocks in Taiwan by genetic analysis of meq oncogene.
    Cheng MC; Lai GH; Tsai YL; Lien YY
    PLoS One; 2024; 19(5):e0303371. PubMed ID: 38728352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.